 Fennec Pharmaceuticals Inc NASDAQ: FENC said it expects to receive a Complete Response Letter CRL from the FDA regarding its marketing application for Pedmark. Related Link: Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity. 